MetaNeb Versus Usual Care During Exacerbations of Cystic Fibrosis: An RCT

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology

Background:

• Cystic Fibrosis (CF) exacerbations increase symptom and treatment burden.
• Patients may prefer less effortful airway clearance techniques (ACTs) during exacerbations.

Purpose of the Study:

• To compare the MetaNeb device with usual ACTs in hospitalized adult CF patients during exacerbations.
• To assess the impact on respiratory function and sputum expectoration.

Main Methods:

• A non-blinded randomized controlled trial involving 30 adult CF patients hospitalized with exacerbations.
• Participants received twice-daily supervised airway clearance for 5-7 days (MetaNeb vs. usual ACTs).
• Primary outcome: ventilation inhomogeneity (lung clearance index - LCI) via multiple breath washout.

Main Results:

• Greater improvement in LCI observed in the MetaNeb group compared to the usual ACTs group (mean difference -0.84).
• Some improvements in respiratory mechanics were noted with MetaNeb.
• No significant differences in other secondary outcomes, including respiratory symptoms, were found between groups.

Conclusions:

• Twice-daily use of the MetaNeb device during CF exacerbations led to improved ventilation inhomogeneity compared to usual ACTs.
• The MetaNeb did not show significant differences in other measured outcomes, such as respiratory symptoms.